B-cell Malignancy clinical trials at UCSD

1 research study open to eligible people

Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
open to eligible people ages 18 years and up
Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
La Jolla, California and other locations

Last updated: August 20, 2026